<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326481</url>
  </required_header>
  <id_info>
    <org_study_id>105BC102</org_study_id>
    <nct_id>NCT01326481</nct_id>
  </id_info>
  <brief_title>Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer</brief_title>
  <acronym>TRC105</acronym>
  <official_title>An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended phase 2 dose and overall safety and
      tolerability of TRC105 when given in combination with capecitabine for the treatment of
      patients with progressive or recurrent metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients were required to sign a consent form prior to undertaking any study-related
      procedures. Prospective patients were screened to determine if they qualified for the study
      within 28 days of enrollment. Patients who qualified received TRC105 i.v. over 1 to 4 hours
      on Day 1, Day 4, Day 8 and Day 15 of the initial 21-day cycle and Day 1, Day 8 and Day 15 of
      every subsequent 21-day cycle in combination with 1000 mg/m2 capecitabine BID for 14 days of
      each 21-day cycle. Those who tolerated TRC105 without any infusion reactions were eligible
      for reduced infusion durations. After 3 cycles of treatment, patients who demonstrated a
      response of complete response (CR), partial response (PR) or stable disease (SD) were
      eligible for additional treatment for up to six months (9 total cycles). Upon discussion with
      TRACON, patients judged by the Principal Investigator to be benefiting from treatment were
      able to continue treatment on this protocol beyond six months.

      Toxicities were graded according to the NCI CTCAE Version 4.0. Patients who exited the study
      for reasons other than drug-related toxicity prior to completion of the first 21-day cycle
      were replaced. Intra-patient dose escalation was not allowed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine</measure>
    <time_frame>1.5 years</time_frame>
    <description>Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D</measure>
    <time_frame>Cycle 2 day 1 (3 weeks)</time_frame>
    <description>Mean trough concentration for patients dosed at 10 mg/kg at cycle 2 day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Positive Immune Response to TRC105</measure>
    <time_frame>1.5 years</time_frame>
    <description>Serial blood samples will be tested for anti-drug antibody (ADA) immune response to TRC105. Patients who are positive at baseline (prior to receiving TRC105) are excluded from analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Objective Response According to RECIST 1.1</measure>
    <time_frame>1.5 years</time_frame>
    <description>The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received TRC105 + capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <description>IV</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>carotuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>oral</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven advanced solid cancer for which curative therapy is not
             available (Part 1 only)

          -  Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)

          -  Measurable disease by RECIST 1.1 criteria (Part 2 only)

          -  Willing and able to consent for self to participate in study

          -  Progressive or recurrent disease after prior systemic chemotherapy regimen

          -  Age ≥ 18 years

          -  ECOG performance status of 0 or 1

          -  Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or
             baseline (except alopecia)

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior treatment with more than one systemic chemotherapy regimen for metastatic
             disease.

          -  Prior treatment with TRC105

          -  History of hypersensitivity reaction to antimetabolite therapy

          -  Receipt of an investigational agent within 28 days of starting study treatment

          -  Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28
             days of starting study treatment

          -  Minor surgical procedures within 14 days prior to first dose of TRC105

          -  History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or
             new evidence of brain or leptomeningeal disease

          -  Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient
             ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the
             past 6 months

          -  Uncontrolled chronic hypertension defined as systolic &gt; 140 or diastolic &gt; 90 despite
             optimal therapy

          -  Past medical history of acquired or inherited coagulopathy including patients with
             known hereditary hemorrhagic telangiectasia

          -  Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days
             prior to first dose with TRC105

          -  Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month

          -  Hemorrhage within 28 days of starting study treatment

          -  Unhealed wounds within 28 days of starting study treatment

          -  History of peptic ulcer disease or gastritis within the past 6 months, unless treated
             for the condition and complete resolution has been documented by
             esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
             related illness

          -  Known active viral or nonviral hepatitis

          -  History of hypersensitivity reaction to human or mouse antibody products

          -  Lung cancer with central chest lesions

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Theuer, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tracon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>February 6, 2019</results_first_submitted>
  <results_first_submitted_qc>February 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRC105</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>CD105</keyword>
  <keyword>Endoglin</keyword>
  <keyword>TRACON Pharma</keyword>
  <keyword>Roswell Park Cancer Institute</keyword>
  <keyword>Department of Defense</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carotuximab (TRC105) Plus Capecitabine</title>
          <description>All patients received TRC105 + capecitabine
TRC105: IV (7.5 or 10 mg/kg weekly)
Capecitabine: oral (1,000 mg/m2 BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>7.5 mg/kg TRC105, 1000 mg/m2 Cape</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>10 mg/kg TRC105, 1000 mg/m2 Cape</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received at least a portion of a dose of TRC105</population>
      <group_list>
        <group group_id="B1">
          <title>Single</title>
          <description>All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at the time of enrollment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="33" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine</title>
        <description>Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.</description>
        <time_frame>1.5 years</time_frame>
        <population>All patients who received at least a portion of a dose of TRC105 enrolled in the dose escalation portion of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Carotuximab (TRC105) Plus Capecitabine</title>
            <description>All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine</title>
          <description>Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.</description>
          <population>All patients who received at least a portion of a dose of TRC105 enrolled in the dose escalation portion of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with DLT at 7.5 mg/kg</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients without DLT at 7.5 mg/kg</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients with DLT at 10 mg/kg</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients without DLT at 10 mg/kg</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D</title>
        <description>Mean trough concentration for patients dosed at 10 mg/kg at cycle 2 day 1</description>
        <time_frame>Cycle 2 day 1 (3 weeks)</time_frame>
        <population>All patients who received full TRC105 doses of 10 mg/kg in cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Single</title>
            <description>All patients dosed at 10 mg/kg TRC105 who received TRC105 + capecitabine
TRC105: IV (10 mg/kg weekly)
Capecitabine: oral (1,000 mg/m2 BID)</description>
          </group>
        </group_list>
        <measure>
          <title>TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D</title>
          <description>Mean trough concentration for patients dosed at 10 mg/kg at cycle 2 day 1</description>
          <population>All patients who received full TRC105 doses of 10 mg/kg in cycle 1.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66668.75" lower_limit="200" upper_limit="129000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Positive Immune Response to TRC105</title>
        <description>Serial blood samples will be tested for anti-drug antibody (ADA) immune response to TRC105. Patients who are positive at baseline (prior to receiving TRC105) are excluded from analysis.</description>
        <time_frame>1.5 years</time_frame>
        <population>All patients who received at least a portion of a dose of TRC105</population>
        <group_list>
          <group group_id="O1">
            <title>Single</title>
            <description>All patients received TRC105 + capecitabine
TRC105: IV
Capecitabine: oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Positive Immune Response to TRC105</title>
          <description>Serial blood samples will be tested for anti-drug antibody (ADA) immune response to TRC105. Patients who are positive at baseline (prior to receiving TRC105) are excluded from analysis.</description>
          <population>All patients who received at least a portion of a dose of TRC105</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Post-Dose Positive Anti-Drug Antibody</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post-Dose Negative Anti-Drug Antibody</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Objective Response According to RECIST 1.1</title>
        <description>The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type</description>
        <time_frame>1.5 years</time_frame>
        <population>Patients who had measurable disease at baseline and received at least one follow up scan were evaluable for the primary efficacy outcome of ORR by RECIST 1.1</population>
        <group_list>
          <group group_id="O1">
            <title>Single</title>
            <description>All patients received TRC105 + capecitabine
TRC105: IV
Capecitabine: oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Objective Response According to RECIST 1.1</title>
          <description>The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type</description>
          <population>Patients who had measurable disease at baseline and received at least one follow up scan were evaluable for the primary efficacy outcome of ORR by RECIST 1.1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected for each patient from the time of informed consent through 28 days following the last dose of study drug. Patients were eligible for participation in the trial until they progressed. The longest duration of AE collection for a given patient was 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single</title>
          <description>All patients received TRC105 + capecitabine
TRC105: IV
Capecitabine: oral</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Unrelated per investigator assessment to TRC105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Unrelated per investigator assessment to TRC105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Unrelated per investigator assessment to TRC105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Unrelated per investigator assessment to TRC105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <description>Unrelated per investigator assessment to TRC105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Suspected related to TRC105 per investigator assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion-related reactions</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Suspected related to TRC105 by the investigator</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Theuer, Medical Monitor</name_or_title>
      <organization>TRACON Pharmaceuticals Inc</organization>
      <phone>8585500780</phone>
      <email>ctheuer@traconpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

